These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28366271)

  • 1. Targeted therapies in the treatment of urothelial cancers.
    Aragon-Ching JB; Trump DL
    Urol Oncol; 2017 Jul; 35(7):465-472. PubMed ID: 28366271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line therapies in metastatic urothelial carcinoma.
    Narayanan S; Harshman LC; Srinivas S
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):341-59, x. PubMed ID: 25836939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.
    Dietrich B; Siefker-Radtke AO; Srinivas S; Yu EY
    Am Soc Clin Oncol Educ Book; 2018 May; 38():342-353. PubMed ID: 30231356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas.
    Aragon-Ching JB
    Urol Oncol; 2017 Jul; 35(7):462-464. PubMed ID: 28625477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
    Aragon-Ching JB; Trump DL
    Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy: new applications in urologic oncology.
    Mullane SA; Bellmunt J
    Curr Opin Urol; 2016 Nov; 26(6):556-63. PubMed ID: 27584023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy for systemic urothelial cancer recurrence].
    Lehmann J; Stöckle M
    Urologe A; 2005 Apr; 44(4):369-74. PubMed ID: 15754166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for urothelial cancer.
    Serrano C; Morales R; Suárez C; Núñez I; Valverde C; Rodón J; Humbert J; Padrós O; Carles J
    Cancer Treat Rev; 2012 Jun; 38(4):311-7. PubMed ID: 22113129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the VEGF pathway in metastatic bladder cancer.
    Mazzola CR; Chin J
    Expert Opin Investig Drugs; 2015; 24(7):913-27. PubMed ID: 26098435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in bladder cancer--an update.
    Black PC; Agarwal PK; Dinney CP
    Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in advanced urothelial carcinoma.
    Verdoorn BP; Kessler ER; Flaig TW
    Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
    Grivas PD; Melas M; Papavassiliou AG
    Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
    Sethakorn N; O'Donnell PH
    BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
    Lu YM; Chien TM; Lin CH; Chai CY; Huang CN
    J Med Case Rep; 2016 Apr; 10():98. PubMed ID: 27091477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.